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Abstract—An expanded computational model of surface
induced thrombin generation was developed that includes
hemodynamic effects, 22 biochemical reactions and 44
distinct chemical species. Surface binding of factors V, VIII,
IX, and X was included in order to more accurately simulate
the formation of the surface complexes tenase and pro-
thrombinase. In order to model these reactions, the non-
activated, activated and inactivated forms were all consid-
ered. This model was used to investigate the impact of
surface bound heparin on thrombin generation with and
without the additive effects of thrombomodulin (TM). In
total, 104 heparin/TM pairings were evaluated (52 under
venous conditions, 52 under arterial conditions), the results
demonstrating the synergistic ability of heparin and TM to
reduce thrombin generation. Additionally, the role of circu-
lating tissue factor (TFp) was investigated and compared to
that of surface-bound tissue factor (TFs). The numerical
results suggest that circulating TF has the power to amplify
thrombin generation once the coagulation cascade is already
initiated by surface-bound TF. TFp concentrations as low as
0.01 nM were found to have a signiﬁcant impact on total
thrombin generation.
Keywords—Surface induced thrombin generation, Anti-
thrombogenic surface, Numerical model, Circulating tissue
factor.
INTRODUCTION
Despite a growing understanding of the coagulation
system, individual thrombotic risk is diﬃcult to esti-
mate. Moreover, the potential eﬃcacy of novel anti-
coagulants or new strategies to limit the risk of device
related thrombosis is diﬃcult to establish without
extensive preclinical and clinical investigations. The
coagulation cascade is complex, particularly when
coupled with a unique, organ speciﬁc, hemodynamic
environment, thereby creating a system that is sensitive
to a variety of parameters, in addition to coagulation
factors. Clotting factors participate in a non-linear
cascade, predominantly initiated by surface bound
tissue factor (TF) via the extrinsic pathway, producing
thrombin, a serine protease. Thrombin, in turn, serves
to activate many components of the cascade, as well as
the conversion of ﬁbrinogen to ﬁbrin, the major com-
ponent of the hemostatic plug. Coagulation pathway
inhibitors, such as antithrombin III (ATIII), tissue
factor pathway inhibitor (TFPI) and activated protein
C (APC) impede cascade reactions reducing the rate of
thrombin production and, ultimately, clot formation.
In addition to reaction pathway kinetics, blood ﬂow
plays an important role in modulating clot formation
by delivering substrates to surface bound TF, while
removing activated clotting factors and inhibitors.
Due to the complex nature of the coagulation cas-
cade, numerical models have been developed in an ef-
fort to elucidate the relationship between clotting
factors, thrombin generation, and thrombus forma-
tion. These models have analyzed the impact of the
geometry of TF regions,20–23,41 the complex chemical
mechanism of coagulation,8,16,17 diffusion and spatial
effects,2,49,50 as well platelets in the presence of
hemodynamics.13,26,27 These models have provided
important insights in the identiﬁcation of dominant
coagulation reactions and those factors, which have
the largest contribution toward clotting disorders.
Obtaining these insights experimentally would have
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been prohibitive and nearly impossible to analyze
without numerical methods.
Devices designed for blood contacting applications
have often been modiﬁed with surface bound heparin
to locally inactivate thrombin.15,40,47 In this regard,
the selection among various heparin types, such as
unfractionated heparin, low molecular weight hep-
arin, or a heparin pentasaccharide, as well as the
optimal choice of heparin surface concentration has
been largely empirical. Such an approach, as related
to the incorporation of surface bound heparin or for
other thrombin inhibitors, dictates a design strategy
that is time intensive and costly. Moreover, the ability
to fully deﬁne failure modes under speciﬁc implant
conditions or to predict the effect, if any, of design
changes to the implantable blood-contacting device
on subsequent performance may be limited. The effect
of surface-bound heparin in limiting surface induced
thrombin generation has yet to be investigated in a
numerical model of coagulation. Of particular interest
is the degree to which heparin reduces the local con-
centration of thrombin as a function of heparin type
and the extent of this effect as compared to other
surface bound inhibitors of thrombin generation, ei-
ther alone or in combination. For example, heparin
serves as an anticoagulant by binding ATIII, thereby
enhancing the capacity of ATIII to inactivate
thrombin and activated factor X. In contrast, in
binding thrombin, thrombomodulin (TM), which may
also be used to modify blood contacting
devices,35,36,43,45 reduces the local concentration of
thrombin and alters its substrate speciﬁcity so that it
preferentially activates protein C.
Previous computational models of coagulation at an
interface have considered surface bound TF, but have
not accounted for the potential eﬀects of circulating
TF. Recent studies have suggested that circulating TF
may play an important role in either the initiation or
propagation of the coagulation cascade. Indeed, a
number of reports have demonstrated a correlation
between circulating TF and venous thromboembolism
(VTE).12,29,51 Nonetheless, the clinical relevance of
circulating TF levels remains poorly deﬁned, particu-
larly, as a potentiating factor for thrombin formation
in the presence of locally expressed, surface bound TF.
We have previously reported the formulation of a
computational model of surface-induced thrombin
generation in a ﬂow ﬁeld, where subendothelial surface
reactions are considered, as well as the eﬀects of
coagulation inhibitors, including ATIII, TFPI, and
APC.18 This model was subsequently used to assess
individual patient risk for VTE in the presence or ab-
sence of a history of oral contraceptive usage.19 We
report, herein, an extended model, which we believe
more accurately describes the formation of surface-
bound prothrombinase and tenase, by incorporating
the phenomenon of direct surface adsorption of non-
activated, activated, and inactivated species. In addi-
tion, the model has also been enhanced to account for
additional surface-bound inhibitory species, speciﬁ-
cally, heparin, as well as circulating plasma TF. This
expanded model has allowed us to evaluate the inter-
active effects of surface bound heparin and TM, as well
as the effect of circulating TF under a variety of ﬂow
and surface conditions..3
METHODS
Thrombin generation initiated by surface-bound TF
under speciﬁed ﬂow conditions is modeled using the
ﬁnite element method (FEM) implemented in COM-
SOL Multiphysics 4.3a. The degree of thrombin for-
mation is controlled by reaction kinetics, diﬀusion, and
convection due to simulated blood ﬂow. Transport of
ﬂuid phase chemicals is governed by 2-D, unsteady
convection–diﬀusion equations. Surface species are
governed by transient diﬀerential equations. Fluid
phase reactions are included in species-speciﬁc partial
diﬀerential equations, while surface reactions are
implemented as boundary conditions. The lower wall,
deﬁned by discrete regions of surface bound TF, TM
and heparin, is a reactive surface with kinetically de-
scribed boundary conditions. The upper wall is far
removed from any diﬀusing species and, therefore, is
treated as an inert surface with a constant ﬂux
boundary condition for all species. All equations and




The initial concentration of all activated compounds
are set to zero with the exception of factor VIIa, which
is set to 1% of the non-activated concentration.33
Mean physiological levels were employed for initial
concentrations of all plasma species, excluding plasma
tissue factor (TFp) (see Supporting Information).
Activated, non-activated, and inactivated forms of
factors V, VIII, IX, and X are able to adsorb and
desorb to and from the lower surface wall, given a ﬁxed
number of speciﬁc surface sites (see Supporting
Information). For surface-bound species, including
TM, tissue factor (TFs), and heparin, the total amount
of surface species (free and complexed) remains con-
stant at the speciﬁed initial level. Initial total levels of
TFp vary from 0 to 100 nM. Complexed factor VIIa
and TFp are initially set to equilibrium values.
Presence of Surface-Bound Heparin and Circulating TF 1073
General
The coagulation pathway is initiated when factor
VIIa binds reversibly to surface-bound TF, forming
extrinsic tenase (Fig. 1). Extrinsic tenase activates
factors X and IX, leading to factors Xa and IXa,
respectively. Subsequently, surface-bound Xas acti-
vates factors VII and V, affording factors VIIa and Va.
Prothrombinase is formed when surface-bound Vas or
Xas complexes with Xa or Va, respectively.
Prothrombinase activates factor VII, as well as factor
II, producing thrombin and establishing a positive
feedback loop with the activation of factors VIII and
V, generating VIIIa and Va. Intrinsic tenase is formed
when surface-bound VIIIas or IXas forms a complex
with IXa or VIIIa, respectively. Intrinsic tenase acti-
vates factor X, which further ampliﬁes the cascade.
Three thrombin inhibitors, including APC, ATIII,
and TFPI are included. Surface-bound TM, which
binds and sequesters thrombin, follows an upstream
region of surface-bound TF. TM-thrombin surface
complexes generate APC, which inactivates Vas and
VIIIas. ATIII binds to thrombin, IXa/IXas, and Xa/
Xas, inactivating these compounds. TFPI binds to ﬂuid
phase Xa, which can bind to surface-bound extrinsic
tenase, eliminating its ability to activate other factors.
The chemical mechanism used herein is based on a
previously described mechanism,18 with several modi-
ﬁcations. The predominant model expansion is the
inclusion of surface sites for factors V, VIII, IX, and X,
which interact with their non-activated, activated, and
inactivated forms. Factors V, VIII, IX, and X bind to
these surface sites and once bound, remained ﬁxed in
position, unable to move due to convective ﬂux or
diffusion, thereby, altering their availability to react
with other species. By including surface sites, many
surface reactions, including the formation of pro-
thrombinase and tenase, are more accurately simu-
lated. In addition to including surface site behavior,
the reaction equations for the inactivation of FVa and
FVIIIa by APC42 and the activation of FV by FXa32
were revised to account for surface behavior in order
to better match experimental results (see Supporting
Information). In the original model, activation of FVII
by FXa was treated as a bulk reaction occurring in the
plasma, but has been revised as a surface reaction, as
experimental evidence suggests that this reaction oc-
curs on a lipid surface.5 Finally, the activation of FVII
by thrombin was replaced by its activation via pro-
thrombinase since this reaction rate is several orders
higher than activation by thrombin.5 Chemical trans-
port is described by convection–diffusion equations
with boundary conditions determined by the chemical
kinetics at each region. Where rate constants have not
been measured due to very fast reaction conditions,
diffusion limited rate constants were used. It is
assumed that enzyme reactions are at equilibrium and
follow Michaelis–Menten kinetics. Speciﬁc rate con-
stants are summarized in the Supporting Information.
Surface-Bound Heparin
Where indicated, surface-bound heparin was incor-
porated as an additional thrombin inhibitor. Heparin
forms a complex with ATIII potentiating its ability to
bind and inactivate thrombin and factor Xa. Three
diﬀerent forms of surface bound heparin, including a
pentasaccharide, a low molecular weight heparin (26
saccharides), and an unfractionated version of heparin
(70 saccharides), each with diﬀerent, literature-deﬁned
rate constants for complexing ATIII, were considered
in this analysis.38
FIGURE 1. Thrombin generation and inhibition pathways. (a) Thrombin (IIa) generation via the extrinsic, intrinsic, and common
pathways. (b) Thrombin inhibition via tissue factor pathway inhibitor (TFPI), antithrombin III, and activated protein C (APC). (c)
Heparin catalyzes thrombin inhibition by potentiating the activity of ATIII.
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Circulating Plasma Tissue Factor
Circulating TFp was modeled as a free species cap-
able of interacting with factor VIIa, forming circulat-
ing extrinsic tenase that could initiate or propagate
coagulation. The diffusivity of microparticle-bound
TFp was estimated using the Stokes–Einstein equation
based -on an average microparticle radius of 500 nm.
The impact of surrounding erythrocytes on the diffu-
sivity of these microparticles was taken into consider-
ation by determining an effective diffusivity, assuming
a hemocrit of 40%, an effective erythrocyte radius of
2.75 lm, and a Brownian diffusivity of 1029 m2/s
(8.6 9 1028 cm2/s for venous shear and 6.6 9
1027 cm2/s for arterial shear).48
Vascular Compartment
The vascular compartment is modeled as a 10 mm
wide, 2-D channel (Fig. 2). Plasma ﬂows from left to
right, passing over a 1 mm region of surface-bound
tissue factor (TFs), followed by a 10 mm downstream
region containing surface-bound TM, representative of
an intact endothelium. In selected simulations, both
surface-bound heparin and TM are present in the
downstream region.
Flow proﬁles were represented by incompressible
Navier–Stokes equations with inlet proﬁles based on
either a simulated venous shear rate of 50 s21 or an
arterial shear rate of 500 s21. Fluid ﬂow was assumed
to be unidirectional and laminar. Consistent with the
Navier–Stokes equation, ﬂow was parabolic with peak
ﬂuid velocity located at the center of the vessel.
Model Outputs of Thrombin Generation
The simulations yielded transient, 2-D concentra-
tion proﬁles for each reactant and product species.
Flow-simulated thrombin generation (FSTG), as ﬁrst
deﬁned by Jordan and Chaikof,18 was used to quantify
the amount of thrombin generated throughout the
simulation. FSTG was deﬁned as the integral over a
60 min simulation time of thrombin generated along
the entire reactive surface, including both TF and TM
regions, normalized by time and reactive surface
length. FSTG facilitated a comparative global analysis
of multiple simulation conditions.
FEM Mesh
While the distance between upper and lower walls
was 10 mm, the chemical diﬀusive boundary layer
thickness was approximately 5 or 10 lm at arterial and
venous shear rates, respectively. In order to capture
transport within this boundary layer, the mesh used in
the ﬁnite element solver was reﬁned signiﬁcantly in the
region adjacent to the reactive surface containing sur-
face-bound TF or TM. Along the reactive surface the
mesh was speciﬁed to have 150 elements along the
1 mm TFs region and 500 elements along the region
containing surface-bound TM. Additionally, the mesh
was reﬁned at the junction of TFs/TM and at the end
of the downstream TM region. Enhanced mesh
reﬁnement was extended out 50 and 100 lm to include
16,447 and 19,052 elements for simulated arterial and
venous shear rates, respectively.
RESULTS
TF Surface Density
The coagulation cascade modeled in these simula-
tions is initiated by surface-bound TF. If the initial
surface density of TF is too low, the coagulation cas-
cade does not propagate, irrespective of other model
FIGURE 2. Model schematic of surface bound tissue factor initiating thrombin generation in a flow field. Fluid enters a 10 mm
diameter blood vessel from the left, with a parabolic flow profile. The fluid, carrying coagulation proteins, passes over a 1 mm
region of surface bound tissue factor (TF), which then activates the coagulation cascade. Immediately downstream is a 10 mm
region of surface bound thrombomodulin (TM), which may also contain surface bound heparin. These surface bound moieties
inhibit coagulation and reduce thrombin formation. Flow simulated thrombin generation, FSTG, is determined by averaging the
thrombin concentration along the TF/TM region over length (11 mm) and time (60 min).
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parameters. However, if the TF surface density exceeds
a deﬁned level, the cascade will propagate under nearly
all conditions and the impact of negative feedback
systems is negligible. This threshold-like behavior is
illustrated in Fig. 3. In the presence of simulated ve-
nous and arterial shear rates, the maximum thrombin
level at the interface of TF and TM containing regions
was measured as a function of varying TF surface
densities with TM surface density held constant at
1000 fmol/cm2. Venous conditions were associated
with a larger chemical boundary layer, which allows
the products of the initiation reaction to remain near
the reactive surface for longer periods of time, leading
to higher levels of thrombin than under similar con-
ditions at arterial shear rates.
Prior studies have demonstrated that below a criti-
cal TF threshold, thrombin levels were less than
10 nM. Above this TF threshold, where explosive
thrombin generation was noted, thrombin concentra-
tions rapidly exceeded 10 nM.18 Therefore, a thrombin
concentration of 10 nM, which surpasses the level
required to induce signiﬁcant platelet activation,3 was
selected as indicative of a locally prothrombotic
microenvironment enabling propagation of the coag-
ulation cascade. Under simulated venous and arterial
shear rates, this threshold occurred at TF surface
densities of 1.3 and 16 fmol/cm2, respectively.
TM Surface Density
TM initially inhibits thrombin generation by form-
ing a complex with thrombin, which alters its proco-
agulant catalytic activity to that which catalyzes the
formation of APC. At a TM surface density of
1000 fmol/cm2, APC generation is transport limited,
such that increasing TM surface density does not
promote further enhancement of local APC concen-
tration (Fig. 4a). Unless otherwise speciﬁed, TM sur-
face density was set at this level in all model
simulations.
Reaction Scheme Time and Length
Thrombin generation is initiated at surface-bound
TF and propagates forward in space and time, moving
downstream past the initial site of surface bound TF.
Within the ﬁrst 60 min after initiation, maximum levels
of thrombin have been achieved at the TF/TM inter-
face (Fig. 4b). Additionally, maximum levels of APC
have been achieved after 60 min, indicating that all key
chemical behavior has been captured within this time
window. The reactive surface is 11 mm long, with
1 mm of surface-bound TF and 10 mm of surface-
bound TM. After 60 min, all major changes in
thrombin and APC have occurred within the reactive
region, indicating that the region is of sufﬁcient length
to model the cascade behavior under both arterial and
venous ﬂow conditions (Figs. 4c and 4d).
Surface-Bound Heparin
Surface-bound heparin forms a complex with ATIII
that serves to inactivate thrombin and factor Xa. The
relative impact of heparin and TM on FSTG was
evaluated under simulated venous and arterial condi-
tions (Figs. 5 and 6). Each of the three different forms
of surface-bound heparin, representing a commercially
available heparin pentasaccharide, low molecular
FIGURE 3. The effect of tissue factor surface density on peak thrombin concentration at the TF/TM interface. Maximum thrombin
concentrations (nM) at the TF/TM interface were measured under varying TF surface densities under (a) venous (50 s21) and (b)
arterial (500 s21) shear rates. TM levels were held constant at 1000 fmol/cm2. A thrombin concentration of 10 nM (dashed line) was
used to indicate a surface threshold of bound TF that would lead to significant thrombin generation and platelet activation. This
‘‘cutoff level’’ occurs just beyond a TF surface density of 1.3 and 16 fmol/cm2 under venous and arterial shear rates, respectively.
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weight heparin (LMWH), and unfractionated heparin;
each displaying distinct reaction kinetics, as reported,
with reaction rates increasing with heparin chain
length.38 As a consequence, simulations revealed that
high molecular weight heparin was most effective at
reducing FSTG, by as much as three orders of mag-
nitude, as compared to the heparin pentasaccharide
and LMWH.
While high levels of TM and heparin successfully
inhibited thrombin generation, simulation studies
conﬁrmed that a combination of moderate levels of
both TM and heparin were synergistic in their ability
to limit thrombin concentration. For instance, under
venous conditions, thrombin formation was fully
inhibited (FSTG< 10 nM) at a TM surface density of
100 fmol/cm2 when combined with a density of surface
bound unfractionated heparin of 3 fmol/cm2. If used
as the sole inhibitory agent, a tenfold higher density of
surface bound TM or heparin would be required to
obtain similar levels of inhibition. Similarly, under
arterial conditions, thrombin formation was fully
inhibited when a TM surface density of 10 fmol/cm2
was combined with a surface concentration of
unfractionated heparin of 3 fmol/cm2. Similarly, ten-
fold or threefold greater levels of TM or heparin,
respectively, would be necessary to achieve comparable
levels of inhibition, if either agent was used alone. In
general, the extent of thrombin inhibition was greater,
FIGURE 4. Defining thrombomodulin, region length, and reaction time as model parameters. (a) Maximum activated protein C
(APC) concentration is measured under venous shear conditions in response to varying TM densities at TF surface densities
below, at, and above the surface bound TF ‘‘cutoff level’’. When TM exceeds 1000 fmol/cm2, APC is transport limited and further
increases in TM have a negligible effect on APC generation. (b) Thrombin and APC concentrations at the TF/TM interface were
measured over 60 min under venous and arterial shear rates. TF surface densities were set to the corresponding cutoff levels and
TM was set to 1000 fmol/cm2. After 60 min all key chemical behavior is captured. (c, d) Thrombin and APC are measured, after
60 min, along the reactive surface (TF and TM) under venous and arterial shear rates with TF densities set to the corresponding
cutoff levels and TM set to 1000 fmol/cm2. Length of 0 mm signifies the upstream boundary of the TF region. All significant
changes are visible along the 11 mm length.
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as represented by a lower FSTG, under arterial con-
ditions. Presumably, this effect is due to the higher
shear rate, which limits the time interval available for
thrombin generation within the reactive region.
Plasma TF Model
Circulating plasma phase TF, TFp, provided an
additional mechanism for initiation and propagation
of the coagulation cascade. The impact of TFp on
FSTG was characterized under both venous and arte-
rial conditions (Table 1). Simulations were conducted
in the presence of surface bound TF (TFs), at or
slightly above the critical surface threshold level, as
well as in the absence of surface bound TF. Under
venous conditions the impact of TFs is rapid near the
cutoff point (1.3 fmol/cm2, Fig. 3). However, begin-
ning at TFp = 0.01 nM, FSTG is enhanced in the
presence of TFp with signiﬁcant increases over that
found with TFs alone. Similar results were observed
under arterial conditions, albeit at higher levels of TFp.
Under arterial conditions, the thickness of the chemi-
cal boundary layer is reduced. Thus, products of the
initiation reactions are more rapidly removed and
higher levels of both plasma or surface-bound TF are
required to achieve thrombin generation levels similar
to those found under venous conditions. As a result,
the levels of FSTG under venous and arterial condi-
FIGURE 5. The effect of distinct surface bound heparin species and thrombomodulin under venous shear conditions. FSTG was
measured in response to varying TM and heparin surface densities, with surface bound tissue factor density set just above the
cutoff level to 1.4 fmol/cm2 and at a shear rate 50 s21. Three different heparin chain lengths were used: short (5 saccharides),
medium (26 saccharides), and long (70 saccharides). While high levels of surface bound TM and heparin alone inhibit thrombin
generation, these results suggest that a combination of moderate levels of TM and heparin work in concert to inhibit the coag-
ulation cascade. For instance, thrombin formation is fully inhibited (FSTG<10 nM) at a TM surface density of 100 fmol/cm2 and at a
surface density of long chain heparin of 3 fmol/cm2. Surface bound TM or heparin alone would require tenfold higher levels to
achieve similar levels of inhibition. Additionally, long chain heparin was significantly more effective at inhibiting thrombin gen-
eration as compared to short chain heparin.
E. V. DYDEK AND E. L. CHAIKOF1078
tions can be several orders of magnitude different,
particularly near any TF threshold.
TFp demonstrated the greatest effect when TFs ex-
ceeds the critical threshold; requiring the least amount
of TFp to noticeably enhance FSTG (0.01 and 1 nM
for venous and arterial conditions, respectively).
However, even when there is an absence of surface
bound TF, TFp is able to initiate and propagate the
coagulation cascade at 1 nm and 10 nM, for venous
and arterial conditions, respectively.
DISCUSSION
A Biochemical Framework for Computational Modeling
of Surface Induced Thrombin Generation in a Flow Field
The chemical model used herein extends a prior
mathematical formulation initially developed by Jor-
dan and Chaikof.18 The current model accounts for
surface absorption of coagulation factors V, VIII, IX,
and X and, therefore, we believe more accurately
accounts for the capacity of the activated forms of
these factors to form surface bound tenase and pro-
thrombinase, as has been noted in a variety of exper-
imental studies.25,31,37,39 In the original model, rates of
tenase and prothrombinase formation were approxi-
mated, based solely on the plasma concentration of the
activated factors adjacent to the reactive surface. In
extending this model, surface-binding sites for factors
V, VIII, IX, and X were included to more accurately
reﬂect the kinetics of surface bound tenase and pro-
thrombinase formation. Speciﬁcally, while the total
number of surface sites was assumed constant, the rate
of surface adsorption and desorption of coagulation
factors was considered proportional to the available
density of surface binding sites. The constant number
of surface sites, bound or unbound, places an addi-
tional limit on the formation of surface species, such as
tenase and prothrombinase. This constraint limits
thrombin generation, which is largely driven by such
surface-bound entities. We accounted for adsorption
and desorption reactions for non-activated, activated,
and inactivated forms of factors V, VIII, IX, and X
resulting in 12 new chemical reactions, greatly
expanding the complexity of the mathematical model.
All told, we believe these changes allow for a more
accurate biochemical representation of the formation
of surface tenase and prothrombinase complexes,
TABLE 1. Flow simulated thrombin generation (FSTG) in response to varying concentrations of circulating tissue factor (TFp) and





0 – 0.3 107.6
0.001 2.9 9 1027 0.4 113.0
0.01 3.1 x 1025 0.5 164.8
0.1 2.9 x 1023 348.2 518.1
1 687.5 851.4 856.8
10 954.6 960.5 960.7





0 – 0.9 1.6
0.001 3.5 9 1028 0.9 1.6
0.01 3.6 9 1026 0.9 1.6
0.1 3.8 9 1024 1.1 2.0
1 2.4 9 1022 19.7 59.5
10 571.5 707.5 711.3
100 857.0 857.9 858.0
TM surface density was set to 1000 fmol/cm2 and coagulation factors and inhibitors were set to mean physiological levels. TFs levels above
and below the cutoff level were considered, as well as the case in which surface bound tissue factor is absent. Under venous conditions the
impact of TFs is rapid near the cutoff point (see Fig. 3), with significant FSTG occurring with only TFs (TFp = 0). However, at TFp = 0.01 nM,
FSTG is enhanced with significant increases over that found with TFs alone. Similar results are achieved under arterial conditions, albeit at
higher levels of TFp. Under both shear rates, the presence of circulating tissue factor potentiates thrombin generation, as indicated by FSTG,
even when TFs is below a critical cutoff level. Thus, TFp reduces the threshold necessary to initiate the coagulation cascade.
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consistent with the current experimental understanding
of the coagulation cascade.
A Combined Model of Surface Bound Heparin and
Thrombomodulin
While many studies have investigated heparin as a
systemic and surface bound anticoagulant, few studies,
either experimental or computational, have deﬁned the
capacity of surface bound heparin to limit local
thrombin formation in the presence of complex ﬂow
ﬁelds or in response to variable local thrombogenic
triggers, such as TF. Few numerical models have been
published that incorporate heparin reaction kinetics.
Byun et al.6 used a simple numerical model consisting
of 5 proteins in a parabolic ﬂow ﬁeld to determine that
ATIII binding to surface-bound heparin does not de-
pend on ﬂow rates. However, this study did not
investigate the role of surface-bound heparin in limit-
ing local thrombin concentrations or determine
threshold values for thrombin generation. Several
in vitro studies have sought to determine optimal
heparin surface concentrations under ﬂow conditions.
Whole blood experiments using a Chandler device
FIGURE 6. The effect of distinct surface bound heparin species and thrombomodulin under arterial shear conditions. FSTG was
measured in response to varying TM and heparin surface densities, with surface bound tissue factor density set just above the
cutoff level to 17 fmol/cm2 and at a shear rate 500 s21. Three different heparin chain lengths were used: short (5 saccharides),
medium (26 saccharides), and long (70 saccharides). While high levels of surface bound TM and heparin alone inhibit thrombin
generation, these results suggest that a combination of moderate levels of TM and heparin work in concert to inhibit the coag-
ulation cascade. For instance, thrombin formation is fully inhibited at a TM surface density of 10 fmol/cm2 and at a surface density
of long chain heparin of 3 fmol/cm2. Surface bound TM or heparin alone would require tenfold or threefold higher levels,
respectively, to achieve similar levels of inhibition. Long chain heparin was significantly more effective at inhibiting thrombin
generation as compared to short chain heparin. Inhibition was more successful under arterial conditions due to a higher shear
rate, which reduced the time available for thrombin generation before inhibition of the coagulation cascade.
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demonstrated improved blood compatibility by
increasing heparin surface density from 6 to 12 pmol
ATIII/cm2.1 Parallel-plate experiments have observed
maximum thrombin inactivation rates at heparin (MW
~14 kD) surface densities greater than 4.4 pM/cm2.44
While these studies consider the impact of a hemody-
namic environment, they do not include local throm-
bin generation, such as that initiated by surface bound
TF. Since heparinized surfaces reduce thrombin gen-
eration, at least in part, due to neutralizing local
thrombin production, we believe it important to in-
clude local triggers in any such model.24,28
A more comprehensive representation of the ability
of heparin or other surface bound thrombin inhibitors to
limit local thrombin levels in response to initiators of
coagulation and in the context of clinically relevant
hemodynamic conditions would provide a very useful
tool to characterize potential failure modes for such
systems. For example, Tseng et al.45 demonstrated the
additive impact of surface bound heparin andTMunder
ﬂow conditions, suggesting that lower surface concen-
trations of each factor would be sufﬁcient to inhibit
thrombin generation, if both factors were incorporated
onto the surface.45 However, due the complexity of the
experimental system, only a single set of surface bound
heparin and TM substrates could be experimentally
evaluated under restrictive set of ﬂow conditions. The
computational model used in this report facilitated the
evaluation of 104 heparin/TMpairings; 52 under venous
ﬂow conditions and 52 under arterial conditions. This
large parameter space provides an approach to both
focus experimental studies and assist in assessing pro-
posed designs of blood contacting surfaces and devices
in a more cost- and time-effective manner.
The Ampliﬁcation Eﬀect of Circulating Tissue Factor
The clinical signiﬁcance of circulating TF is an area
of active investigation.10,14,52 While there is evidence of
correlation between circulating TF and thromboem-
bolism, the mechanistic role of circulating TF remains
incompletely deﬁned.12,30,51 In vivo studies using a
photochemical carotid artery injury model and inferior
vena cava ligation suggest that TF-bearing leukocytes
have little impact on thrombus formation, implying
that surface-bound TF along the vessel wall drives
thrombosis.11 Alternatively, laser induced injury
models provide evidence that both blood-borne and
surface-bound TF are involved in initiating and
propagating thrombosis.7,9 However, results from a
mouse DVT model involving restricted blood ﬂow,
without associated endothelial injury, revealed that
only hematopoietic TF, and not vessel wall TF, initi-
ated the coagulation cascade.46 It remains unclear if
circulating TF promotes the initiation and propagation
of coagulation in a manner similar to that of surface-
bound TF.
Likewise, the relationship between the plasma con-
centration of TF and the initiation of the coagulation
cascade under clinically relevant ﬂow regimes has not
been thoroughly studied. Whole blood experiments
under rocking conditions considered a range of circulat-
ing TF concentrations and showed that 100 fM of relip-
idated TF reduced clotting time by approximately 50%.4
However this threshold-like value was obtained without
considering the presence of surface-bound TF or distinct
hemodynamic ﬂow regimes. When surface-bound TF is
included, parallel-plate experiments demonstrated that
under ﬂow conditions 100 fMof circulatingTF increases
ﬁbrin deposition more than twofold.34 These in vitro
experiments suggest that 100 fM of circulating TF is
sufﬁcient to impact the coagulation cascade. However,
simulations involving TFp, modeled as behaving in a
chemically identical manner to TFs, suggest higher con-
centration thresholds for TFp in order to signiﬁcantly
increase thrombin production. At a concentration of TFs
below which propagation of the coagulation cascade is
not observed, the calculated threshold for TFp to trigger
increased thrombingenerationwas100 pMand1 nMfor
venous and arterial conditions, respectively. Above the
threshold value of TFs (1.3 fmol/cm
2 for venous condi-
tions and 16 fmol/cm2 for arterial conditions), the
threshold value for TFp to trigger increased thrombin
generation was reduced to 10 pM under venous condi-
tions, while remaining unchanged at 1 nM for arterial
conditions. According to these simulated results, TFp
ampliﬁes thrombin generationonce the cascade is already
initiated by TFs. Signiﬁcantly, under venous shear rates,
TFp serves to promote the initiation of the coagulation
cascade, even when the surface density of TFs is insufﬁ-
cient. Clinical studies involving circulating TF are difﬁ-
cult to compare with these results as the method for
reporting TF activity is often expressed in inconsistent
units. However, a study investigating VTE in cancer
patients found higher median levels of circulating TF in
patients with pancreatic cancer (12.67 pM, range 0.05–
112.04 pM) than in those with other cancers (2.01 pM,
range 0.05–43.92 pM).12 Of note, these experimental
values are within the range of the calculated threshold
pro-thrombotic concentrations for circulating TF esti-
mated by our numerical model under simulated venous
conditions.
Model Limitations
The computational model presented herein simu-
lates the kinetics of thrombin generation initiated by a
constant level of surface-bound TF within a uniform,
homogeneous liquid exhibiting simple laminar ﬂow.
This model does not include the behavior of platelets
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and, therefore, does not consider how platelets may
physically limit the availability of surface-bound TF.
Furthermore, the lack of platelet interactions prevents
accounting for the exposure of additional phospholipid
surfaces and the resulting reactions that take place on
the surface of activated platelets. Similarly, the model
does not include the impact of ﬁbrinogen cleavage and
the formation of thrombus, which would also physi-
cally limit the exposure of surface-bound species.
Likewise, while the investigated shear rates are based
on well-characterized venous and arterial conditions,
ﬂow was considered to be non-disturbed and unidi-
rectional. Substantially diﬀerent results were observed
under venous and arterial conditions. Therefore, it is
likely that complex hemodynamic regimes, as noted for
heart valves, venous valves, aneurysms, or for a variety
of blood contacting artiﬁcial organs, will signiﬁcantly
inﬂuence thrombotic failure modes.
CONCLUSIONS
The surface complexes tenase and prothrombinase
are critical to the formation of surface-initiated
thrombin. These surface complexes form when one
species is already adsorbed to the surface and then
binds to another species carried in the plasma. Previ-
ous models have not included adsorbed coagulation
factors and, therefore, have potentially generated
inaccurate results. This model’s focus on surface spe-
cies allowed it to be applied to two cases that are highly
dependent on surface reactions.
The eﬃcacy of surface-bound heparin was com-
pared and combined with that of surface-bound TM.
The simulated results suggest that by using both of
these surface moieties, lower total surface concentra-
tions are needed to achieve similar results to that when
only one species is present. This observation may im-
pact the development of implantable devices, where
consistently obtaining and sustaining high surface
densities of covalently bound species may be chal-
lenging.
While the signiﬁcance of circulating TF is an
ongoing area of research, it has been shown that clin-
ically measured levels of TFp are large enough to
generate a thrombotic response when based on the
currently accepted mechanism of thrombin generation.
Simulated results indicate that concentrations as low as
10 pM are able to noticeably increase thrombin pro-
duction. If it is observed that even lower levels of TFp
are capable of shifting the clinically relevant threshold
for initiation the clotting cascade, this would suggest
that the model may be incomplete and further study
required to determine how TFp is able to have such an
impact. In this case, the power of the computational
model is not in predicting clinical outcomes but in
highlighting the potential for gaps in our mechanistic
description of thrombin formation.
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